SKIN.SW Cassiopea S.p.A. (SIX) up 9.85% pre-market to CHF35.70: watch 50-day signal 11 Mar 2026

SKIN.SW stock jumped 9.85% pre-market to CHF35.70 on 11 Mar 2026 after an opening print at CHF32.00 and intraday highs of CHF36.00. Volume at 2,756 shares is about 1.52x the 3-month average of 1,818 shares, marking high-volume mover status in the Swiss SIX session. Traders are watching the gap above the 50-day average (CHF34.37) for a short-term trend shift. We examine fundamentals, technicals, Meyka AI grade and a model forecast to frame trading and risk points for Cassiopea S.p.A.

Pre-market action: SKIN.SW stock price and volume

Cassiopea S.p.A. (SKIN.SW) opened at CHF32.00 and printed an early high of CHF36.00, lifting the last trade to CHF35.70. The 9.85% pre-market rise arrives on 2,756 shares, above the average 1,818. This relative volume surge confirms the stock meets our high-volume movers filter and suggests stronger buy-side interest in the Switzerland (SIX) session.

One clear signal: price crossed the 50-day average (CHF34.37) while remaining below the 200-day average (CHF37.22). That sets a near-term bias for momentum traders watching follow-through at the open.

Fundamentals snapshot: SKIN.SW stock financials and valuation

Cassiopea reports trailing EPS of -1.27 and a negative PE around -28.13, reflecting clinical-stage losses. Book value per share is CHF1.50 and cash per share is CHF0.25, with a current ratio near 1.98, which supports short-term liquidity. Price-to-book sits very high at 26.30, far above the Healthcare sector average PB of 4.88, reflecting market pricing that assumes future commercial success.

Revenue per share is 0.00 in the trailing twelve months data set, and enterprise value figures are limited in public data. Investors should weigh thin near-term revenue against product pipeline milestones such as Winlevi and Breezula.

Technical read: SKIN.SW stock trend, averages and momentum

Technically, SKIN.SW stock is testing a short-term breakout after clearing the 50-day average (CHF34.37). The 200-day average at CHF37.22 is the next resistance band; a decisive close above CHF37.22 would shift the trend for swing traders.

Volume confirms the move: relative volume is 1.52 and intraday range was CHF32.00–CHF36.00. Watch for follow-through above CHF36.00 on higher volume to validate the breakout. Conversely, a fall below CHF32.00 would negate today’s momentum.

Meyka AI grade and model forecast for SKIN.SW stock

Meyka AI rates SKIN.SW with a score of 62.66 out of 100 — Grade B with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics and analyst consensus. The grade highlights moderate conviction driven by pipeline potential but offset by clinical-stage losses and high price-to-book.

Meyka AI’s forecast model projects CHF44.00 in a 12-month base case, implying an upside of 23.25% from the current CHF35.70. A conservative downside scenario model shows CHF28.00, implying a potential decline of -21.57%. Forecasts are model-based projections and not guarantees.

Sector context and comparables for SKIN.SW stock

SKIN.SW sits in Healthcare — Biotechnology where sector average PE is 30.19 and average PB is 4.88. Cassiopea’s high PB (26.30) and negative earnings reflect biotech valuation dynamics where market value is tied to clinical outcomes. Compared to large-cap healthcare names, SKIN.SW is more speculative and tradeable as a news- and milestone-driven asset.

Investors should compare pipeline milestones and cash runway against peers in topical dermatology and specialty pharma when sizing positions.

Risks and opportunities for SKIN.SW stock traders

Opportunities: successful trial readouts or commercial traction for Winlevi or Breezula could re-rate the stock and validate the high PB multiple. Short-term technical strength creates trade setups for momentum and event-driven traders.

Risks: negative clinical data, funding needs, or weak EU/US commercial uptake would pressure price given negative EPS (-1.27) and elevated valuation. Liquidity is light with average daily volume near 1,818 shares, increasing execution risk on size.

Final Thoughts

SKIN.SW stock showed high-volume pre-market strength on 11 Mar 2026, jumping to CHF35.70 on 2,756 shares. That move cleared the 50-day average (CHF34.37) but the 200-day average (CHF37.22) remains key near-term resistance. Fundamentals show negative EPS (-1.27), high price-to-book (26.30) and a tight cash buffer, so upside hinges on clinical and commercial progress. Meyka AI rates SKIN.SW 62.66/100 (B, HOLD) and its forecast model projects CHF44.00 in 12 months, implying +23.25% upside from CHF35.70; forecasts are model-based and not guarantees. For traders, the current setup fits short-term momentum plays if volume sustains above CHF36.00, while longer-term investors should monitor pipeline milestones and cash runway. For additional company detail visit Cassiopea S.p.A. and see the company visual logo and quote image. Meyka AI provides this AI-powered market analysis platform data as part of our coverage; this is informational and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.